Company Overview and News
Gold Standard Ventures Corp. (TSX:GSV)(NYSE MKT:GSV)(NYSE AMERICAN:GSV) ("Gold Standard" or the "Company") is pleased to announce that it has entered into a revised agreement with a syndicate of underwriters co-led by Macquarie Capital Markets Canada Ltd. and BMO Capital Markets and including Cormark Securities Inc. and PI Financial Corp. (collectively, the "Underwriters"), under which the Underwriters have agreed to increase the size of the previously announced bought deal financing to aggregate gross proceeds of C$25 million (the "Upsized Offering") upon the issuance of 12,196,000 common shares ("Common Shares").
Gold Standard Ventures Corp. (TSX:GSV)(NYSE American:GSV)(NYSE MKT:GSV) ("Gold Standard" or the "Company") is pleased to announce OceanaGold's (TSX:OGC)(ASX:OGC) participation in the non-brokered private placement (the "Private Placement"), previously announced on February 1, 2018. OceanaGold has agreed to maintain their pro rata ownership position of approximately 15.8% of Gold Standard for gross proceeds of approximately C$4.
Gold Standard Ventures Corp. (TSX:GSV)(NYSE AMERICAN:GSV) ("Gold Standard" or the "Company") is pleased to announce that it has entered into an agreement with a syndicate of underwriters co-led by Macquarie Capital Markets Canada Ltd. and BMO Capital Markets (collectively, the "Underwriters"), under which the Underwriters have agreed to buy on a bought deal basis 9,756,100 common shares ("Common Shares") at a price of C$2.
TORONTO, ONTARIO--(Marketwired - Jan. 23, 2018) - Revival Gold Inc. (TSX VENTURE:RVG)(OTCQB:RVLGF) ("Revival Gold" or the "Company"), a growth focused gold exploration and development company, announces the appointment of Diane R. Garrett, Ph.D., as a member and Chair of the Company's Board of Directors.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...